Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Abstract 130: Emotional Evaluation of Outcomes in Facial Reanimation Surgery Using Artificial Intelligence
Boonipat, Thanapoom , Assad, Malke, Lin, Jason , Stotland, Mitchell A. , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 29, 2019 | Volume: 7 | Issue: 4S | Pages: 90-91

10.1097/01.gox.0000558404.15738.44 Get It

Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest
Werf, Christian van der , Lieve, Krystien V.V. , Bos, J. Martijn , Lane, Conor M. , Rosés‐Noguer, Ferran , Aiba, Takeshi , Wada, Yuko , Ingles, Jodie , Leren, Ida S. , Rudic, Boris , Maltret, Alice , Sacher, Frédéric , Skinner, Jonathan R. , Roston, Thomas M. , Tfelt‐Hansen, Jacob , Swan, Heikki, Robyns, Tomas , Ohno, Seiko , Roberts, Jason D. , Berg, Maarten P. van den , Kammeraad, Janneke A.E. , Blom, Nico A, Behr, Elijah R. , Borggrefe, Martin , Haugaa, Kristina H. , Semsarian, Christopher , Horie, Minoru , Till, Janice, Ackerman, Michael J. , Wilde, Arthur A.M. , Horie, Minoru , Behr, Elijah Raphael , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Haugaa, Kristina , Wada, Yuko , van der Werf, Christian , Rosés-Noguer, Ferran , Denjoy, Isabelle , Aiba, Takeshi , Schwartz, Peter J. , Krahn, Andrew D. , Ohno, Seiko , Probst, Vincent , Kannankeril, Prince J. , Blom, Nico A. , Shimizu, Wataru , Leenhardt, Antoine , Ingles, Jodie , Lieve, Krystien V

Mayo Clinic

European Heart Journal | April 26, 2019 | Volume: 40 | Issue: 35 | Pages: 2953-2961

10.1093/eurheartj/ehz309 | PMID 31145795 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), implantable cardioverter-defibrillator (ICD) shocks are sometimes ineffective and may even trigger fatal electrical storms. We assessed the efficacy and complications of ICDs placed in patients with CPVT who presented with a sentinel event of sudden cardiac arrest (SCA) while undiagnosed and therefore untreated. Methods and results We analysed 136 patients who presented with SCA and in whom CPVT was diagnosed subsequently, leading to the initiation of guideline-directed therapy, including β-blockers, flecainide, and/or left cardiac sympathetic denervation. An ICD was implanted in 79 patients (58.1%). The primary outcome of the study was sudden cardiac death (SCD). The secondary outcomes were composite outcomes of SCD, SCA, appropriate ICD shocks, and syncope. After a median follow-up of 4.8 years, SCD had occurred in three patients (3.8%) with an ICD and none of the patients without an ICD (P = 0.1). SCD, SCA, or appropriate ICD shocks occurred in 37 patients (46.8%) with an ICD and 9 patients (15.8%) without an ICD (P < 0.0001). Inappropriate ICD shocks occurred in 19 patients (24.7%) and other device-related complications in 22 patients (28.9%). Conclusion In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.
Stereotactic radiosurgery for idiopathic glossopharyngeal neuralgia: an international multicenter study
Kano, Hideyuki , Urgošík, Dušan, Liščák, Roman , Pollock, Bruce E. , Cohen‐Inbar, Or , Sheehan, Jason P. , Barnett, Gene H. , Mathieu, David , Sisterson, Nathaniel , Lunsford, L. Dade , Mathieu, David , Sharma, Mayur , Silva, Danilo

Mayo Clinic

Journal of Neurosurgery | April 19, 2019 | Volume: 125 | Issue: Supplement_1 | Pages: 147-153

10.3171/2016.7.gks161523 | PMID 27903192 Get It

OBJECTIVEThe goal of this study was to evaluate the outcomes of Gamma Knife stereotactic radiosurgery (SRS) when used for patients with intractable idiopathic glossopharyngeal neuralgia.METHODSSix participating centers of the International Gamma Knife Research Foundation identified 22 patients who underwent SRS for intractable glossopharyngeal neuralgia between 1998 and 2015. The median patient age was 60 years (range 34–83 years). The median duration of symptoms before SRS was 46 months (range 1–240 months). Three patients had unsuccessful prior surgical procedures, including microvascular decompression (MVD) (n = 2) and balloon compression (n = 1). The radiosurgical target was the glossopharyngeal meatus. The median maximum dose was 80 Gy.RESULTSThe median follow-up was 45 months after SRS (range 6–120 months). Twelve patients (55%) had < 4 years of follow-up. Thirteen patients (59%) had initial complete pain relief at a median of 12 days after SRS (range 1–60 days). Three patients (14%) had partial pain relief at a median of 70 days after SRS (range 60–90 days). Six patients (27%) had no pain relief. Among 16 patients with initial pain relief, 5 maintained complete pain relief without medication (Barrow Neurological Institute [BNI] pain intensity score Grade I), 1 maintained occasional pain relief without medication (BNI Grade II), 3 maintained complete pain relief with medication (BNI Grade IIIb), and 7 patients had pain recurrence at a median of 20 months after SRS (range 6–120 months). The rates of maintenance of adequate pain relief (BNI Grades I–IIIb) were 63% at 1 year, 49% at 2 years, 38% at 3 years, 38% at 5 years, and 28% at 7 years. When 7 patients without pain recurrence within 4 years of follow-up were excluded, the rates of maintenance of adequate pain relief were 38% at 5 years and 28% at 7 years. Ten patients required additional procedures (MVD, n = 4; repeat SRS, n = 5; glossopharyngeal nerve block, n = 1). Four of 5 patients who underwent repeat SRS maintained pain relief (BNI Grade I, n = 3; and BNI Grade IIIb, n = 1). No adverse effects of radiation were observed after a single SRS. Two patients developed hyperesthesia in the palatoglossal arch 5 and 8 months after repeat SRS, respectively.CONCLUSIONSStereotactic radiosurgery for intractable, medically refractory glossopharyngeal neuralgia provided lasting pain reduction in 55% of patients after 1 or 2 SRS procedures. Patients who had a poor response or pain recurrence may require additional procedures such as repeat SRS, MVD, nerve blocks, or nerve section. No patient developed changes in vocal cord function or swallowing disorders after SRS in this study.
Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.
Allred, Jacob B., Horvath, Laura E., Bastos, Bruno R. , Erlichman, Charles , Luke, Jason J. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS9087-TPS9087

10.1200/jco.2015.33.15_suppl.tps9087 Get It

Response to “Colorectal Cancer Screening by Stool DNA Testing and Patient Emotional Health”
Eckmann, Jason D. , Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | April 13, 2019 | Volume: 114 | Issue: 5 | Pages: 829-830

10.14309/ajg.0000000000000218 | PMID 30950841 Get It

Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics
Ostrom, Quinn T. , Egan, Kathleen M. , Gerke, Travis , Thompson, Reid C., LaRocca, Renato V., Chowdhary, Sajeel, Eckel‐Passow, Jeanette E. , Armstrong, Georgina , Bernstein, Jonine L. , Claus, Elizabeth B. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Houlston, Richard S. , Jenkins, Robert B. , Wrensch, Margaret , Melin, Beatrice , Barnholtz‐Sloan, Jill S. , Bondy, Melissa L. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Nabors, Burt , Olson, Jeffrey J. , Armstrong, Georgina , Wiencke, John K. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Amos, Christopher I. , Huse, Jason T. , Ostrom, Quinn T

Mayo Clinic

International Journal of Cancer | April 9, 2019 | Volume: 146 | Issue: 3 | Pages: 739-748

10.1002/ijc.32318 | PMID 30963577 Get It

Glioma incidence is highest in non‐Hispanic Whites, and to date, glioma genome‐wide association studies (GWAS) to date have only included European ancestry (EA) populations. African Americans and Hispanics in the US have varying proportions of EA, African (AA) and Native American ancestries (NAA). It is unknown if identified GWAS loci or increased EA is associated with increased glioma risk. We assessed whether EA was associated with glioma in African Americans and Hispanics. Data were obtained for 832 cases and 675 controls from the Glioma International Case–Control Study and GliomaSE Case–Control Study previously estimated to have <80% EA, or self‐identify as non‐White. We estimated global and local ancestry using fastStructure and RFMix, respectively, using 1,000 genomes project reference populations. Within groups with ≥40% AA (AFR ≥0.4 ), and ≥15% NAA (AMR ≥0.15 ), genome‐wide association between local EA and glioma was evaluated using logistic regression conditioned on global EA for all gliomas. We identified two regions (7q21.11, p = 6.36 × 10 −4 ; 11p11.12, p = 7.0 × 10 −4 ) associated with increased EA, and one associated with decreased EA (20p12.13, p = 0.0026) in AFR ≥0.4 . In addition, we identified a peak at rs1620291 ( p = 4.36 × 10 −6 ) in 7q21.3. Among AMR ≥0.15 , we found an association between increased EA in one region (12q24.21, p = 8.38 × 10 −4 ), and decreased EA in two regions (8q24.21, p = 0. 0010; 20q13.33, p = 6.36 × 10 −4 ). No other significant associations were identified. This analysis identified an association between glioma and two regions previously identified in EA populations (8q24.21, 20q13.33) and four novel regions (7q21.11, 11p11.12, 12q24.21 and 20p12.13). The identifications of novel association with EA suggest regions to target for future genetic association studies.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310

10.6004/jnccn.2019.0019 | PMID 30959462 Get It

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus
Feng, Lijie , Murugan, Madhuvika , Bosco, Dale B. , Peng, Jiyun , Ta, Lauren E., Richardson, Jason R. , Shen, Yuxian , Wu, Long‐Jun , Wang, Hai‐Long , Wu, Long-Jun , Liu, Yong , Worrell, Gregory A. , Wang, Hai‐Long

Mayo Clinic

Glia | April 6, 2019 | Volume: 67 | Issue: 8 | Pages: 1434-1448

10.1002/glia.23616 | PMID 31179602 Get It

AbstractMicroglial activation has been recognized as a major contributor to inflammation of the epileptic brain. Seizures are commonly accompanied by remarkable microgliosis and loss of neurons. In this study, we utilize the CX3CR1GFP/+ CCR2RFP/+ genetic mouse model, in which CX3CR1+ resident microglia and CCR2+ monocytes are labeled with GFP and RFP, respectively. Using a combination of time‐lapse two‐photon imaging and whole‐cell patch clamp recording, we determined the distinct morphological, dynamic, and electrophysiological characteristics of infiltrated monocytes and resident microglia, and the evolution of their behavior at different time points following kainic acid‐induced seizures. Seizure activated microglia presented enlarged somas with less ramified processes, whereas, infiltrated monocytes were smaller, highly motile cells that lacked processes. Moreover, resident microglia, but not infiltrated monocytes, proliferate locally in the hippocampus after seizure. Microglial proliferation was dependent on the colony‐stimulating factor 1 receptor (CSF‐1R) pathway. Pharmacological inhibition of CSF‐1R reduced seizure‐induced microglial proliferation, which correlated with attenuation of neuronal death without altering acute seizure behaviors. Taken together, we demonstrated that proliferation of activated resident microglia contributes to neuronal death in the hippocampus via CSF‐1R after status epilepticus, providing potential therapeutic targets for neuroprotection in epilepsy.
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Bezjak, Andrea , Paulus, Rebecca , Gaspar, Laurie E., Timmerman, Robert , Straube, William L., Ryan, William F., Garces, Yolanda I. , Pu, Anthony T. , Singh, Anurag K. , Videtic, Gregory M.M. , McGarry, Ronald C., Iyengar, Puneeth , Urbanic, James J., Sun, A. , Daly, Megan E. , Grills, Inga S., Sperduto, Paul W. , Bradley, Jeffrey D. , Choy, Hak, Bradley, Jeffrey , Paulus, Rebecca , Ryan, William F., Pantarotto, Jason R. , Normolle, Daniel Paul

Mayo Clinic

Journal of Clinical Oncology | April 3, 2019 | Volume: 37 | Issue: 15 | Pages: 1316-1325

10.1200/jco.18.00622 | PMID 30943123 Get It

PURPOSE Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS Medically inoperable patients with biopsy-proven, positron emission tomography–staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.